Is Extrapolation of Foreign QT Data Required? - A Regulatory Perspective

Yuki Ando
Senior Scientist for Biostatistics
Pharmaceuticals and Medical Devices Agency (PMDA)
Disclaimer

• The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated.

• These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, Drug Information Association Inc., DIA and DIA logo are registered trademarks. All other trademarks are the property of their respective owners.
Outline

• Use of foreign TQT data in Japan
• “Extrapolation “ of foreign TQT data
• TQT in PMDA clinical trial consultation meetings
• Summary
Use of foreign TQT data in Japan

Assess the data

- Yes: Japanese TQT Data
- No: Assess the foreign data under proper explanation of using foreign data for Japanese risk assessment

Assess the foreign data under proper explanation of using foreign data for Japanese risk assessment

- Yes: Foreign TQT Data
- No: Foreign Concentration/QT Data

Assess the foreign concentration/QT data under proper condition.

- Yes
- No: Need to show the proper reasons for impossibility of conducting Japanese TQT study
- Need to show scientifically why TQT studies do not need to be conducted

3rd DIA Cardiac Safety Workshop in Japan
May 28-29, 2012 | Tokyo, Japan
Use of foreign TQT studies in Japanese NDA

- The availability of foreign data used to assess the delay of cardiac repolarization should be assessed individually.
- When foreign TQT data is used in Japanese NDAs, a proper explanation of why foreign TQT data is being used for Japanese risk assessment is always necessary.
- The reason foreign TQT data is available for Japanese QT prolongation risk assessments should be included in CTD2.7.2

“Extrapolation” of foreign QT data

• Discussion regarding “extrapolation” of QT data (or TQT) is different from that of confirmatory efficacy trial in bridging strategy.
• TQT study
  – is used to determine whether or not the effect of a drug on the QT/QTc interval in target patient populations should be studied intensively during later stages of drug development.
  – is not intended to identify drugs as being pro-arrhythmic.
“Extrapolation” of foreign QT data

- It is important to
  - Investigate possible ethnic factors
  - Consider cautiously the necessity of additional data collection in Japanese in the late stage drug development in Japan
  - Decide the type, amount of additional data in Japanese
  - Organize various data for comprehensive evaluation of QT prolongation and proarrhythmia risk in Japanese
Use of foreign TQT data

Basic characteristics of
-the drug (and the drugs with similar mechanisms)
-target disease, target population
-non-clinical data of the drug

Before PII or PIII

Foreign TQT
-dosage
-results

Safety data collected so far in foreign countries
-Data from both pre- and post- approval phases

Possibility of ethnic difference
-intrinsic and extrinsic factors
-difference of PK/PD, different putative dose

Safety data obtained so far in Japan
-concentration –QT, ECG data in Phase I
-other available data

Necessity and amount of data should be collected in late-phase clinical development in Japan
Use of foreign TQT data

Basic characteristics of the drug (and the drugs with similar mechanisms)
-target disease, target population
-data of the drug (and the drugs with similar mechanisms)
-Safety data collected so far in foreign countries
-Data from both pre- and post- approval phases

Possibility of ethnic difference
-intrinsic and extrinsic factors
-difference of PK/PD, different putative dose

Safety data obtained so far in Japan
-concentration –QT, ECG data in Phase I
-other available data

Collected Japanese data

QT prolongation and proarrhythmia risk assessment in Japanese

3rd DIA Cardiac Safety Workshop in Japan
May 28-29, 2012 | Tokyo, Japan
TQT in PMDA clinical trial consultation meetings

• We have a certain experience with discussion of
  – clinical data packages including TQT study
  – necessity of TQT study
  – use (possibility of extrapolation) of foreign TQT studies

in PMDA clinical trial consultation meetings.
TQT in PMDA clinical trial consultation meetings

• Although sufficiency of data packages and the necessity of TQT studies became a focal point in the meetings in many cases, there were several cases with the issue of “extrapolation of foreign TQT data”.

Discussion points at consultation meetings

• Results of the foreign TQT study
  – Positive or negative

• Relationship between
  – Dosage used in the foreign TQT study
  – (Dosage that showed positive result)
  – Exposure difference between regions (PK/PD, putative clinical dose)
  – Exposure in special population

• Necessity of additional TQT study in Japan
A positive TQT case

• The foreign TQT study showed positive result.
• Cautious evaluation of safety is needed in subsequent clinical trials.
  – Protecting patients
  – Planning of intensive ECG monitoring
• When planning the subsequent trials, possibility of difference of several factors such as drug exposure between regions.
A positive TQT case (cont.)

• Since appropriate description of possible risk in the drug labeling will be needed, advance consideration is recommended.

• When evaluating QT prolongation risk in Japanese population, exposure associated with recommended dose (including situation in special population, maximum exposure) should be taken into account.
A negative foreign TQT case

• The foreign TQT study showed negative result.
• Exposure associate with the dosage of foreign TQT study did not exceed the exposure associate with the maximum putative dose in Japanese.
• Since QT effect in patients with high exposure is still not unclear, ECG monitoring and concentration measurement should be appropriately planned in subsequent clinical trials.
A negative foreign TQT case (cont.)

• In case like this, necessity of additional TQT study in Japanese may be discussed.
• In such discussion, several aspects should be considered.
  – The objective of TQT study
  – The results of the TQT study
  – Characteristics of the drug
  – Concentration-QT relationship
  – Existing safety event data related to cardiac risk
TQT in PMDA clinical trial consultation meetings

- Availability of foreign TQT study and how to plan subsequent clinical trials should be discussed on a case-by-case basis.
  - Clinical trial consultation meeting may be recommended
- Sufficient explanation of the risk in Japanese based on the integration of data of foreign TQT study and other information should be focus.
- For considering and collecting necessary and sufficient data in later phase drug development, the timing of TQT study and evaluating its data will be critical.
Summary

• For efficient use of foreign TQT study for Japanese NDAs, it is important to
  – Investigate possible ethnic factors
  – consider cautiously the necessity of additional data collection in Japanese in the late stage drug development in Japan
  – decide the type, amount of additional data in Japanese
  – organize various data for comprehensive evaluation of QT prolongation and proarrhythmia risk in Japanese
Summary

• Prospectively planned strategy for
  – exploring possibility of ethnic difference
  – deciding timing and where to conduct TQT study
  – explaining QT prolongation and proarrhythmia risk in various regions based on the TQT data and other safety data

may be important in the era of globally simultaneous clinical development.
Thank you for your attention.